Abstract
Second generation antipsychotics (SGAs) are increasingly employed in the treatment of depression. Adjunctive aripiprizole and olanzapine/fluoxetine combination (OFC) have been approved in the US in the treatment of depression. Quetiapine also appears to be poised for an FDA approval as an adjunctive treatment for resistant depression. Historically, first generation antipsychotics were thought to carry an enhanced risk of certain side effects in the treatment of mood disorders, including an enhanced risk of extrapyramidal symptoms (EPS). The second generation antipsychotics are also known to be associated with a variety of metabolic side effects. The use of SGA in a depressed population may pose risks that differ from use in other conditions such as bipolar disorder and schizophrenia. In this paper, the risk of extrapyramidal and metabolic side effects is reviewed in depressed patients treated with second generation antipsychotics.
Keywords: Major depression, drug treatment, anti-psychotics, toxicity
Current Drug Safety
Title: Safety Considerations of the Use of Second Generation Antipsychotics in the Treatment of Major Depression: Extrapyramidal and Metabolic Side Effects
Volume: 5 Issue: 3
Author(s): Charles DeBattista and Kristina DeBattista
Affiliation:
Keywords: Major depression, drug treatment, anti-psychotics, toxicity
Abstract: Second generation antipsychotics (SGAs) are increasingly employed in the treatment of depression. Adjunctive aripiprizole and olanzapine/fluoxetine combination (OFC) have been approved in the US in the treatment of depression. Quetiapine also appears to be poised for an FDA approval as an adjunctive treatment for resistant depression. Historically, first generation antipsychotics were thought to carry an enhanced risk of certain side effects in the treatment of mood disorders, including an enhanced risk of extrapyramidal symptoms (EPS). The second generation antipsychotics are also known to be associated with a variety of metabolic side effects. The use of SGA in a depressed population may pose risks that differ from use in other conditions such as bipolar disorder and schizophrenia. In this paper, the risk of extrapyramidal and metabolic side effects is reviewed in depressed patients treated with second generation antipsychotics.
Export Options
About this article
Cite this article as:
DeBattista Charles and DeBattista Kristina, Safety Considerations of the Use of Second Generation Antipsychotics in the Treatment of Major Depression: Extrapyramidal and Metabolic Side Effects, Current Drug Safety 2010; 5 (3) . https://dx.doi.org/10.2174/157488610791698325
DOI https://dx.doi.org/10.2174/157488610791698325 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews The Neurobiological Bases for the Pharmacotherapy of Nicotine Addiction
Current Pharmaceutical Design Hydroxyimine NO-Donors; FK409 and Derivatives
Current Topics in Medicinal Chemistry Molecular Basis of Mineralocorticoid Receptor Action in the Nervous System
CNS & Neurological Disorders - Drug Targets Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?
Current Pharmaceutical Design Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Cerebroprotective Functions of HO-2
Current Pharmaceutical Design Lactic Acidosis, Hypotension, and Sensorineural Hearing Loss Following Intentional Metformin Overdose
Current Drug Safety Renal Complications of Fabry Disease
Current Pharmaceutical Design Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets Angiotensin Converting Enzyme (ACE) Inhibitory Peptides: Production and Implementation of Functional Food
Current Pharmaceutical Design Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry Applications of Barton-McCombie Reaction in Total Syntheses
Current Organic Synthesis Translational Pharmacology in Aging Men with Benign Prostatic Hyperplasia: Molecular and Clinical Approaches to Alpha1-Adrenoceptors
Current Aging Science Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets “Vascular Incontinence” and Normal-Pressure Hydrocephalus: Two Commonsources of Elderly Incontinence with Brain Etiologies
Current Drug Therapy Hypertension in Pregnancy: Clinical Manifestations and Treatment
Current Hypertension Reviews Pyrazoline: A Promising Scaffold for the Inhibition of Monoamine Oxidase
Central Nervous System Agents in Medicinal Chemistry Upper Airway Resistance Syndrome
Current Respiratory Medicine Reviews Pharmacology of Adenosine A2A Receptors and Therapeutic Applications
Current Topics in Medicinal Chemistry